Development of a guideline on the safety of nanoparticles – in the context of the establishment of maximum residue limits and veterinary marketing authorisations

This concept paper addresses the need for a specific guideline on the establishment of maximum  residue limits (MRLs) for pharmacologically active nanoparticles, as well as on safety for veterinary medicinal products (VMPs) containing nanoparticles. 

Keywords: Novel therapies, nano, safety, veterinary regulation, persistent nanoparticles, nano-toxicology, nanoparticles, nanotechnology, veterinary medicinal products issued from nanotechnologies

Current version

Concept paper for the development of a guideline on the safety of nanoparticles – in the context of the establishment of maximum residue limits and veterinary marketing authorisations

Draft: consultation closedConsultation dates: 26/04/2024 to 31/07/2024Reference Number: EMA/CVMP/NTWP/143787/2023Summary:

This concept paper addresses the need for a specific guideline on the establishment of maximum  residue limits (MRLs) for pharmacologically active nanoparticles, as well as on safety for veterinary medicinal products (VMPs) containing nanoparticles. 

Comments should be provided using this template. The completed comments form should be sent to [e-mail]